Bachelor of Medicine, Bachelor of Surgery

Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research

Retrieved on: 
Wednesday, November 8, 2023
Survival, FRCP, Research, Uveal melanoma, International Congress on Tuberculosis, Trae tha Truth, Nivolumab, University of Liverpool, Bachelor of Medicine, Bachelor of Surgery, DOR, Melanoma, Liver, Clatterbridge Cancer Centre NHS Foundation Trust, Doctor of Philosophy, Ipilimumab, Development, Lung, 8th Plenary Session of the Central Committee of the League of Communists of Serbia, Disease, Hypotension, Liver disease, Metastasis, RP2, Itch, Uvea, Immunotherapy, ORR, Chills, University, Society, Melanoma Research, Patient, Toxicity, Fatigue, Pharmaceutical industry, Fever

The data were presented by Dr. Joseph Sacco during a Plenary Session at the 20th International Congress of the Society for Melanoma Research in Philadelphia.

Key Points: 
  • The data were presented by Dr. Joseph Sacco during a Plenary Session at the 20th International Congress of the Society for Melanoma Research in Philadelphia.
  • The median duration of response (DOR) at the data cutoff was 11.47 months (range of 2.78 to 21.22 with responses ongoing).
  • RP2 was generally well tolerated both as monotherapy and in combination with nivolumab with no additive adverse events observed.
  • “These data from the trial cohort evaluating RP2 as monotherapy and in combination with nivolumab in metastatic uveal melanoma are highly promising,” said Robert Coffin, President and Chief Research & Development Officer at Replimune.

Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells

Retrieved on: 
Tuesday, November 7, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, MB, Neoplasm, Metastasis, OTC Markets Group, Cancer, MD, US Foods, Liver, Doctor of Philosophy, Phenotype, Kidney, Trypsinogen, Malignancy, Extracellular matrix, Tissue, Lung, Growth, Chymotrypsinogen, Survival rate, Skin, Pancreatic cancer, University, Gene, Master of Science, Brain, Tumor microenvironment, Bachelor of Medicine, Bachelor of Surgery, PDAC, Apoptosis, Patient, Breast, Gene expression, PRP, Prostate, PPCB, Medical imaging, Pharmaceutical industry

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment by decreasing the fibrotic tissue and its malignancy (ability to spread into surrounding tissues).

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment by decreasing the fibrotic tissue and its malignancy (ability to spread into surrounding tissues).
  • Various methods, including apoptosis (programmed cell death) and viability analysis, live/dead assays, and RT-qPCR (real time quantification of gene expression) analyses confirmed PRP enhances the sensitivity of pancreatic tumor cells to standard chemotherapy treatment and decreases expression of genes related to chemoresistance.
  • A synergistic ratio of 1:6 inhibits growth of most tumor cells.
  • Orphan Drug Designation status of PRP has been granted from the US Food and Drug Administration (FDA) for treatment of pancreatic cancer.

Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annua

Retrieved on: 
Thursday, November 2, 2023
Patient, MCP1, Aes, IRR, TP53, Bachelor of Medicine, Bachelor of Surgery, AST, Bone marrow, CD47, Azacitidine, Observation, Nausea, Clinical trial, Autoimmune disease, AZA, Safety, Cancer, Cellular, ALT, Combination therapy, Transplant, CD40, AML, Pharmaceutical industry

AUSTIN, Texas and DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the presentation of topline data from the dose escalation portion of its Phase 1 A/B clinical trial of SL-172154 as monotherapy and in combination with azacitidine (AZA) in primarily R/R AML and HR-MDS patients. These data will be featured in a poster presentation at the 65th ASH Annual Meeting, which is being held both virtually and in San Diego, CA from December 9-12, 2023.

Key Points: 
  • “Response rates are historically low for heavily pretreated relapsed/refractory AML and HR-MDS patients.
  • Notably, preliminary data shows anti-leukemic effects detected in previously untreated TP53m-MDS and R/R AML patients.
  • In bone marrow, abundant staining of SL-172154 was observed, along with a dose-dependent increase in phagocytic cells within mature myeloid immune cell compartments.
  • Reduction in leukemic blasts was associated with an increase in mature myeloid and phagocytic cell phenotypes.

Family Matters Fertility Centre Launches Innovative Fertility Tourism Program Welcoming Americans

Retrieved on: 
Friday, October 27, 2023
Knowledge, Female, Gynaecology, Education, Birmingham Women's Fertility Centre, System, Health, Bachelor of Medicine, Bachelor of Surgery, Hope, Family, Obstetrics, Endocrinology, HIV, HIV Clinical Resource, Bachelor, IVF, Transport, Dream, COVID-19, Freezing, Assisted reproductive technology, Police, Woman, Reproductive medicine, Safety, Anxiety, Infertility, Patient, Empathy, Parent, Birth control, Nursing

South Africa’s female-led fertility clinic, Family Matters Fertility Centre is distinguished by its first female-led approach, which is designed to meet the individual requirements and convenience of female patients.

Key Points: 
  • South Africa’s female-led fertility clinic, Family Matters Fertility Centre is distinguished by its first female-led approach, which is designed to meet the individual requirements and convenience of female patients.
  • Family Matters Fertility Centre's journey began in February 2020, just before the global COVID-19 pandemic took hold.
  • Family Matters Fertility Centre has launched ‘Fertility Tourist Program’ to cater to a wider audience.
  • Family Matters Fertility Centre is more than just a medical facility; it's a place where dreams of parenthood are fulfilled and hope transforms into joy, welcoming both American and international patients on their path to parenthood.

Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, FDA, ATTR, The New England Journal of Medicine, Science, Therapy, Bachelor of Medicine, Bachelor of Surgery, Cardiomyopathy, Medication, Use, Viral hepatitis, Symantec Endpoint Protection, Conference, American Heart Association, Quarter, Acquisition, Haemophilia, Clinical trial, TTR, Truly Madly Deeply – Ultra Rare Tracks, Growth, Polyneuropathy, Risk, Hypertension, RNA interference, ALN, Roche, Sanofi, Amyloidosis, Patient, APOLLO, ASCVD, Phase 1, Pharmaceutical industry, Video game, Medical device, Aluminium, Regeneron Pharmaceuticals, Alnylam Pharmaceuticals, Inclisiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights.
  • Attained over 3,790 hATTR amyloidosis patients with polyneuropathy worldwide on commercial treatment with ONPATTRO or AMVUTTRA as of September 30, 2023.
  • Alnylam announces today that it will present a review of its RNAi platform and pipeline progress at a virtual R&D Day on December 13, 2023.
  • Financial Results for the Quarter Ended September 30, 2023

Heartpoint Global Wins Top Honor in TCT 2023 Shark Tank Innovation Competition

Retrieved on: 
Wednesday, October 25, 2023
Ventricular septal defect, Patient, Research, Way, Tumor antigens recognized by T lymphocytes, CRF, MD, Orthostatic hypertension, Jon, Citizenship, Rehabilitation, University, Pulmonary artery, TCT, Diagnosis, Pulmonary hypertension, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery

NEW YORK , Oct. 25, 2023 /PRNewswire/ -- HeartPoint Global is pleased to announce that INTELLISTENT® the company's novel multi-lumen stent system for interventional adjustment of pulmonary blood flow in congenital heart disease, was the winner in the Shark Tank Innovation Competition at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

Key Points: 
  • HeartPoint Global's INTELLISTENT® is a groundbreaking multi-lumen stent system for interventional adjustment of pulmonary blood flow to treat PAH-CHD.
  • Seth Bogner, Chairman and CEO of HeartPoint Global said, "We are deeply honored to be bestowed with this prestigious award.
  • The TCT Shark Tank Innovation Competition has partnered with the Jon DeHaan Foundation for six years to provide a $200,000 award for the winner.
  • The Shark Tank Innovation Competition aims to identify and showcase the most groundbreaking concepts in modern cardiovascular medicine.

Monroe College Celebrates the Class of 2023 at Annual Commencement Ceremony for Saint Lucia Campus Graduates

Retrieved on: 
Tuesday, October 24, 2023
Former, Principal, Faculty, Graduation, Monroe College, Accounting, General Education, Ministry of home affairs, Catholic Church, Grand marshal, Crime, Sir Arthur Lewis Community College, International Hospital Federation, School, Cabinet, Vocational education, Ambassador, Administration, Vocation, Ministry, Simon G. Atkins Academic & Technology High School, Excellency, Republic, Bachelor of Medicine, Bachelor of Surgery, Student, Restaurant, Business, Partnership, St. Michael's Church, Master's degree, Hospitality management studies, Caribbean Journal of Science, Information technology, Public service, Nick Dean (Paralympic administrator), Social justice, Sustainable development, Gender Affairs Advisor to the Chief of Staff, Nursing, Innovation, Science, College, Education

CASTRIES, Saint Lucia, Oct. 24, 2023 /PRNewswire-PRWeb/ -- Monroe College, the New York-based institution offering Bachelor's and Master's degree programs from its campus in Saint Lucia, held its Annual Commencement on Sunday for local graduates.

Key Points: 
  • CASTRIES, Saint Lucia, Oct. 24, 2023 /PRNewswire-PRWeb/ -- Monroe College , the New York-based institution offering Bachelor's and Master's degree programs from its campus in Saint Lucia, held its Annual Commencement on Sunday for local graduates.
  • Monroe College President Marc Jerome and other senior administrators joined local campus faculty and staff, as well as special dignitaries, at the graduation ceremony, which recognized and celebrated the academic achievements of 82 students in the Saint Lucia campus Class of 2023.
  • Among those offering welcoming remarks to the graduates and their guests were College President Marc Jerome and Augustus Small, Dean of Administration for the Saint Lucia campus.
  • More than 1,500 students have earned their degree through Monroe College's Saint Lucia campus since its establishment in 2007.

Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

Retrieved on: 
Monday, October 23, 2023
General Health, Health, Pharmaceutical, Clinical Trials, Oncology, Neoplasm, DXD, EGFR, Arm, PD-L1, NSCLC, AstraZeneca, Incidence, ESMO, Progression-free survival, Trae tha Truth, Fatigue, Stomatitis, Congress, European Society for Medical Oncology, PFS, MD, Docetaxel, CRS, Doctor of Philosophy, HIV disease progression rates, R, Nausea, Lung, ADC, Daiichi Sankyo, Dor, TSE, Risk, Histology, ORR, ILD, Anemia, Platinum, Lung cancer, Weakness, Cancer, Patient, OS, Death, Toxicity, Neutropenia, UCLA Health, Medical imaging, Fine chemical, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery

Median PFS was 4.4 months in patients treated with datopotamab deruxtecan compared to 3.7 months with docetaxel.

Key Points: 
  • Median PFS was 4.4 months in patients treated with datopotamab deruxtecan compared to 3.7 months with docetaxel.
  • Results also showed a confirmed objective response rate (ORR) of 26.4% in patients treated with datopotamab deruxtecan compared to an ORR of 12.8% in patients treated with docetaxel.
  • Median PFS was 5.6 months in patients treated with datopotamab deruxtecan compared to 3.7 months in those treated with docetaxel.
  • At the March 29, 2023 data cut-off, 52 patients remained on treatment with datopotamab deruxtecan and 17 remained on docetaxel.

USA Health Children's & Women's Hospital Goes Live with AdaptX for Maternal Health Equity Initiative

Retrieved on: 
Thursday, October 19, 2023
Science, Health care, Health, Bachelor of Medicine, Bachelor of Surgery, Hope, Mortality, RN, Disease, Health equity, Partnership, Obstetrics, Mother, Cone Health Women's Hospital, Investment, Patient, Hospital, MSN, Canadian Foundation for Healthcare Improvement, IHI, Nursing, MD, Merck

SEATTLE, Oct. 19, 2023 /PRNewswire-PRWeb/ -- AdaptX®, a self-serve clinical management solution company, today announced the go-live of Alabama-based USA Health Children's and Women's Hospital with AdaptX's Obstetrics Advisor™ solution to improve maternal health equity, in partnership with the Institute of Healthcare Improvement (IHI) and with generous support from Merck for Mothers.

Key Points: 
  • "AdaptX is transforming the way we approach maternal health equity," said Vicki Curtis, MSN, RN, RNC-OB, director of women's services for USA Health Children's and Women's Hospital.
  • As part of this innovative maternal health initiative, USA Health Children's & Women's Hospital is receiving unique change management training and support from the IHI's quality improvement experts, reflecting the IHI's commitment to improving health equity.
  • I'm hopeful that this partnership and approach will show practical solutions that will close maternal health equity gaps."
  • "The AdaptX team is honored to partner with USA Health and the IHI to improve maternal health equity," said Warren Ratliff, chief executive officer of AdaptX.

Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Retrieved on: 
Tuesday, October 10, 2023
Congress, Drug, Central nervous system, Cell, Risk, Gene, MECP2, AAV, Poster, Bachelor of Medicine, Bachelor of Surgery, CET, ESGCT, European Society of Gene and Cell Therapy, CNS, Rett syndrome, National Center for Advancing Translational Sciences, Pharmaceutical industry

DALLAS, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that it will present data on its TSHA-102 program in evaluation for Rett syndrome during two poster presentations at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress, taking place in Brussels, Belgium from October 24-27, 2023.

Key Points: 
  • DALLAS, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that it will present data on its TSHA-102 program in evaluation for Rett syndrome during two poster presentations at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress, taking place in Brussels, Belgium from October 24-27, 2023.
  • TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy that utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression.
  • The Company will present new preclinical in vitro data supporting the miRARE technology, as well as initial clinical data from the first adult patient dosed with TSHA-102 in the REVEAL Phase 1/2 adult trial.
  • Poster presentation details are as follows:
    Presenters: Emdadul Haque, Ph.D., Director, Translational Sciences, and Fred Porter, Ph.D., Chief of Staff and Technical Operations Officer, Taysha Gene Therapies
    Poster Session Date/Time: Wednesday, October 25 at 17:00-18:15 CET and Thursday, October 26 at 20:30-21:30 CET
    Presenter: Benit Maru, MBChB, Ph.D., Chief Medical Officer and Head of Clinical Development, Taysha Gene Therapies
    Poster Session Date/Time: Wednesday, October 25 at 18:15-19:30 CET and Thursday, October 26 at 19:30-20:30 CET